Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary

Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.

Original reporting
Published Nov 16, 2026, 1:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary — source image
Decision brief

The 30-second read

$APVOBearishHigh
01

Why it matters

The earnings miss and loss expansion are likely to trigger a sell‑off, while the clinical data may provide a longer‑term upside narrative.

02

Market read

First‑report earnings for a micro‑cap biotech; material for traders focused on biotech earnings and clinical milestones.

03

What to watch

Potential future grant funding (Washington CARE Fund) and upcoming regulatory interactions could offset short‑term loss concerns.

Relevance 8/10Novelty 8/10Timing: after‑hours filing

Background

Aptevo Therapeutics filed its Q3 2026 10‑Q, summarizing financials and clinical updates.

Company-level read

Ticker impact

$APVOBearishHigh confidence
Context

Aptevo reported a widened net loss and a diluted EPS of -$5.19 for Q3 2026, plus clinical trial data showing 79% CR/CRi in TP53‑mutated AML patients.

Expected impact

downward pressure as investors digest the larger loss and modest clinical progress.

Evidence & confidence

The 10‑Q is the first public disclosure of these results; loss widening and weak EPS are material for a micro‑cap biotech.

Market effects

May dampen sentiment in the oncology biotech niche.

Limited to U.S. biotech investors.

Low; impact confined to APVO and similar small‑cap biotech stocks.

Counterpoint

Some investors may view the 79% CR/CRi rate as a positive catalyst despite the earnings miss.

Key entities

  • Aptevo Therapeutics Inc.

    Biotech company developing targeted therapies for cancer.

Related articles

$APVOHighAI 8/10

Aptevo reports Q3 results, mipletamig AML trial data

Aptevo Therapeutics (APVO) reported a Q3 2026 net loss of $6.5M, down from $7.5M in Q3 2025. Cash reserves fell to $8.3M. The company shared positive clinical data for mipletamig in AML treatment, with 79% remission rate in a small trial. It aims to complete Phase 1b trials by year-end and plans regulatory interaction in early 2027. Aptevo raised $4.5M in August via warrant inducement and private placement.

$APVOMedAI 8/10

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibits 99.1 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Ten of 47 patients re

$APVOMedAI 8/10

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-